NEWS
202376
PR Heartseed Announces Positive 26-week Data for the First Patient in the Phase 1/2 Clinical Trial (LAPiS Study) Dosed With HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure
2023613
Media Heartseed selected as "Six companies that have made their name in the cardiovascular space" by LABIOTECH
2023525
PR Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
2023319
Media News article about the initiation of a clinical trial of Heartseed was published in Nature Medicine.
2023314
PR Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences.
2023216
Congress Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's Next Generation Cardiovascular Drug Development in April 25-27.
2023216
Congress Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's iPSC Manufacturing Summit in May 2-4.
2023210
PR Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 - a cell therapy designed to restore heart function in people with advanced heart failure